This page has been archived on the Web

Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.

Archived

This page has been archived on the Web.

Health product recall

Methoxacet - C1/8 (2016-01-22)

Starting date:
January 22, 2016
Posting date:
February 2, 2016
Type of communication:
Drug Recall
Subcategory:
Drugs
Hazard classification:
Type III
Source of recall:
Health Canada
Issue:
Product Safety
Audience:
General Public, Healthcare Professionals, Hospitals
Identification number:
RA-56950

Affected Products

Methoxacet - C1/8

Reason

Product did not meet stability specification for Codeine Phosphate assay.

Depth of distribution

Distributed down to retailers in Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, Quebec and Saskatchewan.

Affected products

Methoxacet - C1/8 

DIN, NPN, DIN-HIM
DIN 02236872
Dosage form

Caplets

Strength
  • Methocarbamol 400 mg
  • Acetaminophen 325 mg
  • Codeine phosphate 8 mg
Lot or serial number
  • Lot 656308
  • Lot 658255
  • Lot 658849
  • Lot 659640
  • Lot 661859
  • Lot 665580
  • Lot 669624
      Companies
      Recalling Firm
      Teva Canada Ltd.
      30 Novopharm Court
      Toronto
      M1B 2K9
      Ontario
      CANADA
      Marketing Authorization Holder
      Teva Canada Ltd.
      30 Novopharm Court
      Toronto
      M1B 2K9
      Ontario
      CANADA

      Date modified: